Daily News: December 28, 2017

Wells Fargo Agents Omnicell Revolver Amendment


According to an 8-K filing, Omnicell amended its 2016 credit agreement, with Wells Fargo Securities acting as sole lead arranger and Wells Fargo Bank acting as administrative agent.

Under the new amendment, the revolving credit facility was increased from $200 million to $315 million and a $200 million term loan facility created. Each of the facilities matures on January 5, 2021.

Loans under the facilities bear interest, at the company’s option, at a rate equal to either (a) the LIBOR Rate, plus an applicable margin ranging from 1.50% to 2.25% per annum based on the company’s consolidated total net leverage ratio, or (b) an alternate base rate equal to the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50% and (iii) LIBOR for an interest period of one month, plus an applicable margin ranging from 0.50% to 1.25% per annum based on the company’s consolidated total net leverage ratio. Undrawn commitments under the revolver are subject to a commitment fee ranging from 0.20% to 0.35% per annum based on the company’s consolidated total net leverage ratio on the average daily unused portion of the facility.

The company is permitted to make voluntary prepayments at any time without payment of a premium or penalty.

Omnicell is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety.